1. Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. (June 2019) Authors: Wesolowski, Robert; Sharma, Neelesh; Reebel, Laura; Rodal, Mary Beth; Peck, Alexandra; West, Brian L.; Marimuthu, Adhirai; Severson, Paul; Karlin, David A.; Dowlati, Afshin; Le, Mai H.; Coussens, Lisa M.; Rugo, Hope S. Journal: Therapeutic advances in medical oncology Issue: Volume 11(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗